pSivida, known for drug delivery products to treat back-of-the-eye diseases, has entered a funded technology evaluation agreement with a pharmaceutical company to assess pSivida's bioerodible Durasert drug delivery technology in ophthalmology.
Subscribe to our email newsletter
pSivida is independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis).
In addition, the company has partnered with Pfizer for the development of a product to treat glaucoma and ocular hypertension.
Currently, pSivida is focused on the treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.